IDEAYA Biosciences, a precision medicine oncology company, announced strong third-quarter 2024 financial results and highlighted significant progress across its pipeline of targeted therapies. The company achieved key milestones in its darovasertib, IDE397, and IDE161 programs, including successful FDA interactions and positive clinical data. IDEAYA is well-positioned to advance its portfolio of potential first-in-class therapies for patients with various solid tumors.